Clinical Trial Update: 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

The National Cancer Institute completed a Phase 2 trial of tanespimycin (17-AAG) in relapsed or refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2011-05-30